DE60234642D1 - Verhinderung von hautlappennekrose in der plastischen chirurgie - Google Patents

Verhinderung von hautlappennekrose in der plastischen chirurgie

Info

Publication number
DE60234642D1
DE60234642D1 DE60234642T DE60234642T DE60234642D1 DE 60234642 D1 DE60234642 D1 DE 60234642D1 DE 60234642 T DE60234642 T DE 60234642T DE 60234642 T DE60234642 T DE 60234642T DE 60234642 D1 DE60234642 D1 DE 60234642D1
Authority
DE
Germany
Prior art keywords
necrosis
lapse
prevention
skin
plastic surgery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234642T
Other languages
German (de)
English (en)
Inventor
Jonathan S Stamler
Michael R Zenn
Eric J Toone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Application granted granted Critical
Publication of DE60234642D1 publication Critical patent/DE60234642D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60234642T 2001-12-06 2002-12-02 Verhinderung von hautlappennekrose in der plastischen chirurgie Expired - Lifetime DE60234642D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33617501P 2001-12-06 2001-12-06
PCT/US2002/036138 WO2003049593A2 (en) 2001-12-06 2002-12-02 Prevention of flap necrosis in plastic surgery

Publications (1)

Publication Number Publication Date
DE60234642D1 true DE60234642D1 (de) 2010-01-14

Family

ID=23314894

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234642T Expired - Lifetime DE60234642D1 (de) 2001-12-06 2002-12-02 Verhinderung von hautlappennekrose in der plastischen chirurgie

Country Status (8)

Country Link
US (1) US20060153931A1 (enExample)
EP (1) EP1463440B1 (enExample)
JP (2) JP4563679B2 (enExample)
AT (1) ATE450187T1 (enExample)
AU (1) AU2002365036B2 (enExample)
CA (1) CA2467245A1 (enExample)
DE (1) DE60234642D1 (enExample)
WO (1) WO2003049593A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005235308B2 (en) 2004-04-19 2011-12-01 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151240A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
DK2658551T3 (da) 2010-12-29 2020-09-21 Strategic Science & Tech Llc Behandling af erektil dysfunktion og andre indikationer
CN105878172A (zh) 2010-12-29 2016-08-24 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
WO2020185674A1 (en) * 2019-03-08 2020-09-17 South Dakota Board Of Regents A vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing
CN112843241B (zh) * 2021-01-14 2023-07-25 中国药科大学 可生物响应的一氧化氮供体型聚合物前药及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
JP2599031B2 (ja) * 1990-11-30 1997-04-09 宇部興産株式会社 高純度亜硝酸アルキルエステルの製造法
ES2092460T3 (es) * 1994-05-27 2001-02-01 Cellegy Pharma Inc Composicion dadora de oxido nitrico para el tratamiento de trastornos anales.
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5797887A (en) * 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
WO1998050430A2 (en) * 1997-05-02 1998-11-12 Somatogen, Inc. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
AU764921B2 (en) * 1998-12-14 2003-09-04 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6359182B1 (en) * 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof

Also Published As

Publication number Publication date
AU2002365036A1 (en) 2003-06-23
WO2003049593A2 (en) 2003-06-19
EP1463440A2 (en) 2004-10-06
AU2002365036B2 (en) 2006-09-21
CA2467245A1 (en) 2003-06-19
EP1463440A4 (en) 2008-01-23
EP1463440B1 (en) 2009-12-02
US20060153931A1 (en) 2006-07-13
JP4563679B2 (ja) 2010-10-13
JP5266191B2 (ja) 2013-08-21
JP2005511708A (ja) 2005-04-28
WO2003049593A3 (en) 2004-02-19
ATE450187T1 (de) 2009-12-15
JP2010047619A (ja) 2010-03-04

Similar Documents

Publication Publication Date Title
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
MX2010004549A (es) Composiciones y métodos bacteriostáticos o bactericidas.
ECSP099427A (es) Barra de Tierra Segunda Generación 16 conexiones
DE60234642D1 (de) Verhinderung von hautlappennekrose in der plastischen chirurgie
ATE457716T1 (de) Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
BR0312023A (pt) Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
EA200200431A1 (ru) Фармацевтические композиции, обеспечивающие повышенные концентрации лекарства
DE50310516D1 (de) Fredericamycin-derivate
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BRPI0510613A (pt) cisteaminas para tratar complicações de hipercolesterolemia e diabete
CY1113286T1 (el) Συνθεση με στροντιο και βιταμινη d για την προφυλαξη ή/καιθεραπευτικη αντιμετωπιση των παθησεων των χονδρων ή/και των οστων
ATE505488T1 (de) Modulator von coagulationskaskaden und fibrinolytischen kaskaden
ATE552031T1 (de) Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
WO2006048829A3 (en) Preparation of chitin and derivatives thereof for cosmetic and therapeutic use
CY1109513T1 (el) Φαρμακευτικη συνθεση μικροσφαιριδιων για την προληψη του ακρωτηριασμου διαβητικου ποδιου
SE0401342D0 (sv) Therapeutic compounds
BRPI0515582A (pt) 3-(2-hidroxifenil)pirazóis e seu uso como moduladores de hsp90
EA200870535A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ С ИСПОЛЬЗОВАНИЕМ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
Tang et al. Use of tranexamic acid to reduce bleeding in burns surgery
ATE341343T1 (de) Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
ATE480244T1 (de) Neue, hyaluronsäure oder hyaluronsaure derivate und collagenase enthaltende pharmazeutische zusammensetzungen zur topischen behandlung von wunden, verbrennungen und geschwüren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition